HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide

Simona Sica, Andrea Bacigalupo

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The use of high dose posttransplant cyclophosphamide (PT-CY) introduced by the Baltimore group approximately 10 years ago has been rapidly adopted worldwide and is becoming a standard for patients undergoing unmanipulated haploidentical (HAPLO) transplants. PT-CY has been used following nonmyeloablative as well as myeloablative conditioning regimens, for bone marrow or peripheral blood grafts, for patients with malignant and nonmalignant disorders. Retrospective comparisons of HAPLO grafts with conventional sibling and unrelated donor grafts have been published and suggest comparable outcome. The current questions to be answered include the use of PT-CY for sibling and unrelated donors transplant, possibly in the context of prospective randomized trial.
Original languageEnglish
Pages (from-to)78-82
Number of pages5
JournalAdvances in Hematology
Volume2016
DOIs
Publication statusPublished - 2016

Keywords

  • Hematology

Fingerprint Dive into the research topics of 'HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide'. Together they form a unique fingerprint.

Cite this